The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1386
March 19, 2012
View Complete Issue         Table of Contents 2019 
Extended-Release Exenatide (Bydureon) for Type 2 Diabetes
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Extended-Release Exenatide (Bydureon) for Type 2 Diabetes
March 19, 2012 (Issue: 1386)
The FDA has approved a once-weekly extendedrelease formulation of exenatide (Bydureon – Amylin), an injectable glucagon-like peptide-1 (GLP-1) receptor agonist, for treatment of type 2 diabetes.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Extended-Release Exenatide (Bydureon) for Type 2 Diabetes
Article code: 1386b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.